Avastin slows progress of breast cancer in trial
CHICAGO (Reuters) - The addition of Genentech Inc’s cancer drug Avastin to chemotherapy slows the progress of breast cancer at two different doses, according to results of a large international trial released on Saturday.
More: continued here
Leave a Reply
You must be logged in to post a comment.